Investors Sell Mylan (MYL) on Strength (MYL)
Traders sold shares of Mylan (NASDAQ:MYL) on strength during trading hours on Thursday. $73.37 million flowed into the stock on the tick-up and $87.55 million flowed out of the stock on the tick-down, for a money net flow of $14.18 million out of the stock. Of all stocks tracked, Mylan had the 0th highest net out-flow for the day. Mylan traded up $0.37 for the day and closed at $40.69
Several brokerages have issued reports on MYL. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Deutsche Bank set a $50.00 price target on Mylan and gave the stock a “buy” rating in a report on Wednesday, January 24th. Wells Fargo & Co set a $43.00 price target on Mylan and gave the stock a “hold” rating in a report on Thursday, January 18th. TheStreet upgraded Mylan from a “c” rating to a “b-” rating in a report on Wednesday, January 17th. Finally, Susquehanna Bancshares reiterated a “positive” rating and issued a $55.00 price target (up previously from $47.00) on shares of Mylan in a report on Thursday, January 25th. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Mylan presently has an average rating of “Buy” and an average price target of $45.37.
The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.95 and a current ratio of 1.13. The company has a market capitalization of $20,946.46, a price-to-earnings ratio of 31.76, a price-to-earnings-growth ratio of 1.09 and a beta of 1.35.
In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.69% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of MYL. Pzena Investment Management LLC increased its position in shares of Mylan by 84.1% during the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock valued at $712,770,000 after acquiring an additional 10,381,697 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Mylan during the fourth quarter valued at approximately $137,023,000. Millennium Management LLC increased its position in shares of Mylan by 3,005.3% during the fourth quarter. Millennium Management LLC now owns 2,905,317 shares of the company’s stock valued at $122,924,000 after acquiring an additional 3,005,317 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Mylan by 74.7% during the third quarter. Schroder Investment Management Group now owns 3,026,172 shares of the company’s stock valued at $93,388,000 after acquiring an additional 1,294,400 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Mylan by 30.3% during the fourth quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock valued at $225,715,000 after acquiring an additional 1,239,089 shares during the last quarter. 76.86% of the stock is owned by institutional investors.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.